MWM
BMY.RT

Mission Wealth Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Mission Wealth Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-19,409
Closed -$13K – 459
2020
Q4 		$13K Buy
19,409
+130
+0.7% +$277 ﹤0.01% 410
2020
Q3 		$43K Buy
+19,279
New +$55.1K ﹤0.01% 358

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Mission Wealth Management's BMY.RT Position: Q1 2021 in Review

Mission Wealth Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 19,409 shares — an estimated $13K sold.

Mission Wealth Management first reported a position in BMY.RT in Q3 2020 and held it in 2 quarters. The position peaked at $43K in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Mission Wealth Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Mission Wealth Management sold 19,409 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $13K.
  • Mission Wealth Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q3 2020 and held it in 2 quarters.
  • Mission Wealth Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $43K in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Mission Wealth Management's 13F filing for Q1 2021, filed 10 May 2021.